ABT Stock Price Today (November 2026) — Abbott Laboratories Analysis & Key Metrics 2026-11-06
Abbott Laboratories (ABT) is trading at $109.93, down 3.23% today (as of November 2026).The stock is trading above its 50-day and 200-day moving averages.
- According to consensus analyst estimates, the 1-year price target is $118.52 (7.8% upside).
- Volatility is moderate (33.77% annualized), between 25% and 40%.
- From the latest financial filings: Revenue grew 14.50% in the latest quarter compared with the same quarter a year earlier. Debt is 0.63 times shareholders' equity.
ABT Stock Analysis: Key Metrics & Valuation (November 2026)
Key figures from the latest data
Abbott Laboratories - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $217.34B
P/E Ratio
Forward P/E: 17.61
Revenue Growth
Latest quarter vs year ago
Analyst Target
+7.8% upside potential
Key Investor Questions About ABT
What the latest data shows
ABT is trading above its 50-day and 200-day moving averages, and its RSI of 58.8 is in the neutral zone (between 30 and 70).
- Technicals: Neutral (RSI 58.78) (Uptrend: above 50- and 200-day averages)
- Fundamentals: Revenue +14.5%, debt/equity 0.63x
Revenue grew 14.50% in the latest quarter compared with the same quarter a year earlier.
- Total debt is $32.72B (0.63 times equity).
- 30-day volatility is 33.77% annualized, which counts as moderate (between 25% and 40%).
52-Week Trading Range
Over the past year, ABT stock traded between $80.89 and $128.83 and currently trades in the middle of that range.
Volatility & Risk Profile
30-day volatility is 33.77% annualized, which counts as moderate (between 25% and 40%). Beta 0.09: the stock has moved much less than the market.
Institutional & Insider Ownership
Institutions own 81.92% of the shares, and short interest is 1.12% of the float.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Abbott Laboratories Insider Sold Shares Worth $406,000, According to a Recent SEC Filing
Are You Overpaying For Abbott Stock Versus Its Rivals?
Latest TickZen Insights
All insights →No TickZen article on ABT yet. Our newest analysis:
Explore More Analysis for ABT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
No upcoming report date yet
Frequently Asked Questions
Common investor questions about Abbott Laboratories
Abbott Laboratories (ABT) is currently trading at $109.93. The RSI (14-day) is 58.8, in the neutral zone (between 30 and 70). Wall Street analysts have a consensus "Buy" recommendation. The mean analyst price target of $118.52 implies 7.8% upside from current levels. 30-day volatility is 33.77% annualized, which counts as moderate (between 25% and 40%).
Based on current valuation metrics for Abbott Laboratories (ABT): The trailing P/E ratio is 40.87. The forward P/E is 17.61, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 3.72. Price-to-Sales is 3.94. Different industries trade at different multiples, so these figures are most useful next to Medical Devices peers.
Based on 26 analysts covering ABT, the consensus price target is $118.52. This represents a 7.8% upside from the current price of $109.93. The range spans from a low target of $100.00 to a high target of $130.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Abbott Laboratories (ABT) pays a dividend with a current yield of approximately 2.29%. The annualized dividend rate is $2.52 per share. The payout ratio is 78.7%, which is relatively high—earnings cover the dividend but there's limited room for increases. The most recent ex-dividend date was Oct 15, 2026.
Key risks for Abbott Laboratories (ABT) shown in the latest data: 1. Moderate volatility (33.8% annualized, between 25% and 40%). 2. Moves in the broader stock market (Beta 0.09: the stock has moved much less than the market).
Here is Abbott Laboratories's (ABT) current debt and financial health profile: Total debt stands at $32.72B. The debt-to-equity ratio is 0.63x, which is moderate and generally manageable for most companies. The company holds $5.60B in cash and equivalents. Free cash flow is positive at $6.76B, providing a cushion for debt servicing and shareholder returns.